FDA Approves Seasonal Influenza Vaccine Fluarix For Pediatric Use

Main Category: Respiratory / Asthma
Also Included In: Infectious Diseases / Bacteria / Viruses;  Pediatrics / Children's Health;  Regulatory Affairs / Drug Approvals
Article Date: 20 Oct 2009 - 1:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:not yet rated

Healthcare Prof:not yet rated


The U.S. Food and Drug Administration approved use of the seasonal influenza vaccine Fluarix for children ages 3 years to 17 years. Previously, this vaccine, which contains inactivated (killed) influenza A and B viruses, had been approved for use in adults, ages 18 years and older.

The safety and effectiveness of Fluarix for use in children ages 3 years and older is documented by a U.S. study comparing 2,115 children who received Fluarix with 1,210 children who received Fluzone, a different influenza vaccine already licensed by the FDA for use in children ages 6 months and older. Study results showed that children 3 years and older vaccinated with Fluarix and Fluzone produced similar amounts of antibodies in the blood at levels considered likely to be protective against seasonal influenza.

Fluarix is a seasonal influenza vaccine not intended to protect against the 2009 H1N1 influenza virus.

"This approval of an additional seasonal influenza vaccine for children provides help in protecting them against influenza," said Karen Midthun, M.D., acting director of the FDA's Center for Biologics Evaluation and Research. "Children are very vulnerable to the influenza virus and are more likely to be hospitalized for associated problems."

With today's approval, there are now four companies approved by the FDA to manufacture seasonal influenza vaccine for use in children.

Influenza is far more dangerous than the common cold for children, who often require medical care, especially if they are younger than 5 years. It is best to vaccinate children each fall, but vaccination also can occur in the winter months when influenza season often peaks.

Common adverse events experienced after administration of Fluarix are typical of those for flu shots and include pain, redness, and swelling at the injection site as well as irritability, loss of appetite, and drowsiness.

Because Fluarix contains a small amount of egg protein, it should not be administered to anyone allergic to eggs or egg products.

Source: U.S. Food and Drug Administration

View drug information on Fluzone Preservative-free.


Article adapted by Medical News Today from original press release.
Visit our respiratory / asthma section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
U.S. Food and Drug Administration. "FDA Approves Seasonal Influenza Vaccine Fluarix For Pediatric Use." Medical News Today. MediLexicon, Intl., 20 Oct. 2009. Web.
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/167908.php>

APA
U.S. Food and Drug Administration. (2009, October 20). "FDA Approves Seasonal Influenza Vaccine Fluarix For Pediatric Use." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/167908.php.

Please note: If no author information is provided, the source is cited instead.


Respiratory / Asthma

What is Asthma?

Asthma is a disease affecting the airways that carry air to and from your lungs. People who suffer from this chronic condition (long-lasting or recurrent) are said to be asthmatic. Read more...

Most Popular Articles



Follow Our Respiratory News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Respiratory / Asthma Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »